The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including ongoing digitisation and the emergence of new types of liquid biopsies. Medtech: Going steady explores these issues in more detail and reveals insights from the latest consensus forecasts out to […]
Share:
The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including ongoing digitisation and the emergence of new types of liquid biopsies.
Medtech: Going steady explores these issues in more detail and reveals insights from the latest consensus forecasts out to 2028.
Look out for the Evaluate Vantage Medtech World Preview, coming soon.
By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.
